Soleno Therapeutics Inc (NASDAQ:SLNO) Director Edgar Engleman Buys 1,085,480 Shares

Soleno Therapeutics Inc (NASDAQ:SLNO) Director Edgar Engleman bought 1,085,480 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $1.84 per share, with a total value of $1,997,283.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Soleno Therapeutics Inc (NASDAQ:SLNO) traded up $0.01 during trading on Thursday, hitting $1.83. 10,900 shares of the company were exchanged, compared to its average volume of 46,786. The firm has a market capitalization of $18.30, a price-to-earnings ratio of -1.14 and a beta of 6.00. Soleno Therapeutics Inc has a fifty-two week low of $1.32 and a fifty-two week high of $4.55.

A number of research analysts have recently issued reports on SLNO shares. Maxim Group set a $25.00 target price on shares of Soleno Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. ValuEngine upgraded shares of Soleno Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, October 6th. Finally, cut their target price on shares of Soleno Therapeutics from $25.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply